CERN - Cerner Corporation
71.38 0.00 (0.00%)
After hours: 4:18PM EDT
| Previous Close | 71.83 |
| Open | 71.28 |
| Bid | 70.74 x 1300 |
| Ask | 75.14 x 1100 |
| Day's Range | 71.30 - 71.98 |
| 52 Week Range | 48.78 - 76.47 |
| Volume | 1,242,004 |
| Avg. Volume | 2,406,192 |
| Market Cap | 22.727B |
| Beta (3Y Monthly) | 0.81 |
| PE Ratio (TTM) | 39.44 |
| EPS (TTM) | 1.81 |
| Earnings Date | Oct 23, 2019 - Oct 28, 2019 |
| Forward Dividend & Yield | 0.72 (1.02%) |
| Ex-Dividend Date | 2019-06-17 |
| 1y Target Est | 74.56 |
- American City Business Journals
Starboard Value shrinks stake in Cerner
Now that Starboard Value has two seats on Cerner's board and a say in operational and cost structures, the activist investor is decreasing its already small stake in the health IT company.
- American City Business Journals
Cerner jumps into senior living with latest venture
Cerner has partnered with a planned wellness community development company to provide health care services to seniors using the company's technology.
- Simply Wall St.
Does Cerner Corporation (NASDAQ:CERN) Create Value For Shareholders?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- American City Business Journals
Cerner exec: New partnership will use data to drive down drug costs
The pilot program and partnership between Cerner and Duke Clinical Research Institute has the potential to make clinical research more cost effective through automating and analyzing data collection.
- InvestorPlace
3 Keys to Investing in Next-Gen Healthcare Stocks
Picture a bizarre clothing store for a moment …Source: Shutterstock You walk in. An employee sizes you up and asks you if there's anything in particular you're looking for. After learning that you're a size "large" and that you'd like some new dress shirts, the employee takes you to a table covered with them. All of the shirts are the same size. All XL, extra-large."Strange," you think, and go to another table covered with shirts. All the shirts are the same size. All XL.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Stranger," you think, and go to another table covered with shirts. Once again, all the shirts are the same size. All XL.Sensing your confusion, the employee explains the store's "one size fits all" policy. The owners know people come in many shapes and sizes, but XL is the only size of clothes they can get from their suppliers.You walk out of the "one size fits all" store, thinking it's one of the most ridiculous things you've ever seen.A "one size fits all" clothing store isn't much different than America's healthcare system.Lacking the resources to treat us as individuals -- with different genetic makeups, different diets, and living in different environments -- doctors frequently resort to treating patients with "one size fits all" procedures and medicines. And since most doctors rush patients in and out of the office to boost profits, the pressure to use sub-par, "one size fits all" treatments is massive.Don't get me wrong: Our approach to health and medicine is light years ahead of where it was in the 1800s. Bloodletting is no longer a "go to" move for doctors.However, many of the decisions made by today's healthcare professionals will look medieval when compared to the treatments of the near future. They simply don't take into account that every case is different -- that we are all unique. Take the drug commercials you see on television … which go on to list lots of horrible side effects of popular drugs (which don't work for everyone who takes them).Soon, we'll say goodbye to those types of treatments. That's because the age of customized, "precision" healthcare is getting started. The result will be a massively improved healthcare system … and some of the biggest wealth building opportunities of your life.In today's essay, I'll describe the three key innovations that will take us into the age of precision medicine. Investors will want to pay attention. In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in healthcare, it creates giant ripple effects in the economy that enrich those who know what's happening. Trillion-Dollar Innovation 1: Genome SequencingEvery cell in your body has a set of genetic instructions that dictate what you look like, what your athletic abilities are, what your mental abilities are, what diseases you're likely to get, and dozens of other key things that make you YOU.This set of instructions is called your genome. Determining exactly what your genome says is a process called genome sequencing.In 2003, an international research organization called The Human Genome Project sequenced a human genome for the first time. The project's price tag was an enormous $3 billion.Thanks to incredible advances in computing power, that same sequencing can be performed today for less than $1,000. And in a few years the price will be as low as a dinner for two.Genome sequencing is a critical part of precision medicine because it allows medical professionals to get an incredibly detailed analysis of who you are. As a result of this information, doctors can recommend treatments that are right for you.Sixteen years ago, getting this kind of detailed information was prohibitively expensive. But now that costs are down more than 99% and poised to go down even more, genome sequencing is about to go mainstream.Genetic testing will become part of regular medical care … just like taking your pulse and your blood pressure. It's going to usher in an era of much more effective healthcare. In large part to innovation 2 … Trillion-Dollar Innovation 2: Digital Patient RecordsIt's one thing to have lots of information. It's an entirely different -- and more valuable -- thing to be able to analyze that information and use it to make quality decisions.This is where digital patient records come in.Genome sequencing will produce vast amounts of information that will need to be stored and analyzed. Just as the processing power of our computers has increased by leaps and bounds since 2003, our ability to collect and store information has increased as well. This continued growth is a key part of precision medicine. That's because genome sequencing is going to generate a stupendous amount of information.It is predicted that the amount of storage capacity for all human genome data will increase to 40 exabytes by 2025. To put that into perspective, experts believe all videos on YouTube will require 1-2 exabytes of storage and Twitter will require .001 to .017 exabytes.As for analyzing all that data, we come to Innovation 3 … Trillion-Dollar Innovation 3: AI DoctorsAs you can guess, we're not going to sift through some of the world's largest data sets with a pen and paper in hand.We're going to use artificial intelligence (AI) to perform advanced data analysis. AI programs will sift through data to identify treatments that work for patients with specific genetic conditions.These programs will be able to do more "thinking" in one minute than millions of doctors could do in a decade. It's going to revolutionize healthcare.In fact, I believe that within the next 30 years, AI will know how various combinations of molecules will affect patients on the individual level. We'll have giant databases of patients and their genetic makeups … and we'll be able to test new drugs with computer simulations. The time it takes to devise, test, and produce new life-saving drugs will be massively condensed. Plus, the cost of doing it all will plummet.We'll have vast databases of human genomes and the ability to create and test new customized treatments in seconds. It could easily become the most valuable technology on the planet. Again, this is many years away, but I believe it's going to happen. Summing UpOne size fits allThanks to the technological limitations of the past, our healthcare system is based on treatments that are not tailored to your genetic makeup. We're using "shotgun" approaches instead of targeted approaches.However, thanks to cheap and widespread genome sequencing, digital record keeping, and artificial intelligence, we're about to enter an amazing era of precision, personalized medicine.Over the next 20 years, the healthcare system we know and don't love will change dramatically. We'll look back at some of today's treatments as medieval.Remember: In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in the industry, it creates giant ripple effects. That's why the precision medicine revolution is one of the greatest wealth building opportunities of your life.The opportunities are not in the old school big pharma names like Johnson & Johnson. They are in precision medicine and the technologies that will enable it.Everything from digital records company Cerner (NASDAQ:Cern) to gene testing pioneer Illumina (NASDAQ:ILMN) to contract research services firm IQVIA Holdings (NYSE:IQV) will take the lead in the future of precision medicine.And keep an eye on the IPO market here as well. We'll see waves of early stage companies going public … many with the potential to not only revolutionize medicine, but revolutionize your net worth as well.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 3 Keys to Investing in Next-Gen Healthcare Stocks appeared first on InvestorPlace.
- GlobeNewswire
Cerner, Duke Clinical Research Institute Launch New Solution to Innovate Clinical Research
Cerner Corporation (CERN), a global health platform and innovation company, has announced the development of the Cerner Learning Health NetworkSM to help clinicians more easily and efficiently gain health insights and guide care. Cerner aims to automate data collection from multiple sources, including the electronic health record (EHR), to rapidly give medical researchers access to important information that has the potential to transform patient care. Through combined technology and expertise, Cerner and the Duke Clinical Research Institute (DCRI) have joined together to pilot the Cerner Learning Health Network and innovate clinical research registries in the process.
- American City Business Journals
VA transfers 23.5M patient health records to Cerner’s KC data center
The transfer comes as part of Cerner's $16.1 billion contract to develop a new electronic health record system to replace the VA's existing offering — and be interoperable with Defense Department data.
- Zacks
OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?
OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.
- American City Business Journals
Cerner's Amazon cloud deal will deliver 'pretty disruptive' solutions, capabilities
Cerner chose Amazon Web Services as its preferred cloud provider, creating a partnership that could drive health IT innovation.
- GlobeNewswire
Cerner Leads New Era of Health Care Innovation
Cerner Corporation (CERN), a global health platform and technology company, today announced a multi-faceted, strategic collaboration with Amazon Web Services, Inc. (AWS), an Amazon.com company, to accelerate health care innovation across the globe. As part of this agreement, Cerner is naming AWS its preferred cloud provider.
- Thomson Reuters StreetEvents
Edited Transcript of CERN earnings conference call or presentation 24-Jul-19 8:30pm GMT
Q2 2019 Cerner Corp Earnings Call
- GuruFocus.com
Parnassus Fund 2nd Quarter Commentary
Discussion of markets and holdings Continue reading...
- American City Business Journals
Hot IPO company Livongo's CEO was once a fierce rival with its founder
On the day of Livongo's soaring IPO, CEO Zane Burke recalls his once fierce rivalry with founder and chairman Glen Tullman.
- American City Business Journals
Cerner's voluntary separations achieve $40M of its targeted $200M in cuts
Cerner's quarterly report reflects activist investor Starboard Value LP's influence, as it focuses on aggressively improving its operating margins.
- Zacks
MDRX or CERN: Which Is the Better Value Stock Right Now?
MDRX vs. CERN: Which Stock Is the Better Value Option?
- Zacks
Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss
Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.
- Motley Fool
Cerner Delivers As Expected in the Second Quarter
The healthcare technology provider met its revenue guidance and beat its adjusted earnings guidance, thanks primarily to growth in its services business.
Motley FoolCerner Corp (CERN) Q2 2019 Earnings Call Transcript
CERN earnings call for the period ending June 30, 2019.
- Zacks
Cerner (CERN) Q2 Earnings Top Estimates
Cerner (CERN) delivered earnings and revenue surprises of 3.13% and -0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cerner Reports Second Quarter 2019 Results
KANSAS CITY, Mo., July 24, 2019 -- Cerner Corporation (Nasdaq: CERN) today announced results for the 2019 second quarter that ended June 29, 2019. Bookings in the second.
- American City Business Journals
Cerner-supported company faces scrutiny over medical billing, technology
Cerner invested $266 million in Essence Group Holdings Corp. and its medical technology arm Lumeris in July 2018. Now, the St. Louis-based companies are facing a whistleblower lawsuit and a troubling audit by the U.S. Department of Health and Human Services.
- Simply Wall St.
Do Directors Own Cerner Corporation (NASDAQ:CERN) Shares?
Every investor in Cerner Corporation (NASDAQ:CERN) should be aware of the most powerful shareholder groups. Generally...
- Zacks
What's in the Offing for Cerner's (CERN) Earnings in Q2?
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.
